Following former J&J MedTech Neurovascular Worldwide President Mark Dickinson’s announcement last week that he was leaving Johnson & Johnson after a 26-year career with the world’s second-largest device company, Christian Cuzick announced his promotion to the role.
“I look forward to working with our incredible team as we continue the mission to change the trajectory of stroke,” Cuzick wrote on LinkedIn.
“Over my past 20 years at Johnson & Johnson, I have had the privilege of working closely with numerous talented teams both in the U.S. and internationally,” he said. “Our collaboration has been instrumental in driving global business success through strong relationships and a collective commitment to innovation and our customers.
“Currently, 1 in 4 individuals will experience a stroke at some point in their lives, underscoring the importance of effective prevention, timely and equitable intervention, and comprehensive rehabilitation strategies,” he continued. “As I transition into my new role, I am excited to meet and hear from our customers and team members across the world. Together, we will drive change that improves stroke care and positively impacts patients’ lives, shaping the future of neurovascular health.”
J&J MedTech has reportedly been exploring a sale of its neurovascular business, which was previously known as Cerenovus. J&J last week named Michael Bodner as the new group chair of Electrophysiology and Neurovascular.
Cuzick had served as VP of U.S. product marketing for J&J MedTech Electrophysiology since October 2024, according to his LinkedIn profile, and before that was VP of commercial operations and strategic enablement for J&J MedTech North America since 2017. Cuzick also held finance roles for J&J’s Vision Surgical, Janssen Canada, Global Surgery, Medical Device & Diagnostics and LifeScan.
Medtech pay analysis: Johnson & Johnson discloses executive pay and new security measures
